북미 지역 라이선스 및 파트너십 MOU
2 4월 2024
Cizzle 생명공학 홀딩스 plc
("Cizzle", "Cizzle Biotechnology", or "the Company")
Strategic Licensing and Partnership Memorandum of Understanding for North America
Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has signed a non-binding Memorandum of Understanding ("MoU") for a strategic and exclusive licensing agreement to develop and offer its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer, throughout the USA and Canada ("North America").
The new partnership is intended to incorporate the Company's existing relationship with Corepath Laboratories, a full-service cancer reference laboratory, as announced on 6 May 2022, through a dedicated, recently incorporated, US based company Cizzle Bio Inc ("BIO"). As set out below, and subject to binding documentation, the proposed royalty arrangements with CorePath will be restructured to enable the Company to gain significant cash flows from new royalty payments and significant cost savings. All planned expenditure related to clinical trials and the commercialization of diagnostic tests for the CIZ1B biomarker in the USA are expected to be funded directly by BIO. In addition, the Company will benefit from the free issue of shares in BIO. BIO is paying a non-refundable upfront fee of US$100,000 within 30 days of signing the MoU for a 120-day exclusivity period to complete the formal legally binding agreement.
주요 하이라이트
· The MoU envisages Cizzle providing an exclusive licence to BIO to develop and market clinical diagnostic assays based on the CIZ1B biomarker to facilitate the early detection of lung cancer in North America
· Cizzle will receive an up-front payment of US$100,000 within 30 days as a non-refundable fee to grant BIO an exclusive negotiating period of 120 days
· Subject to entering binding documentation, Cizzle will receive minimum advance royalty payments of US$2.3 million over a period of 30 months, payable as to US$0.3 million on signing the binding agreement and a further US$1.0 million on each of the fifteenth and thirtieth month anniversaries of signing as part of annual royalty fees of 10% of net sales
· BIO intends to fully fund all expenditure on development, clinical trials, accreditation and marketing of diagnostic tests for the CIZ1B Biomarker in North America which would represent a significant saving on current planned expenditure by the Company
· Cizzle will participate in the ownership of BIO through a grant of a 10% equity stake in BIO for no cash consideration
· Cizzle will benefit from inventions and improvements to CIZ1B technology for sale in the rest of the world
자세한 내용은
Cizzle's vision is to meet the challenges of early lung cancer detection, reduce premature cancer deaths, improve survival rates and increase quality of life for cancer patients by helping detect cancer as early as possible through a simple blood test.
On 26 March 2024, the Company completed a placing raising gross proceeds of £620,000, which will be utilised towards completing Cizzle's first proposed commercial test to detect CIZ1B, further protect its Intellectual Property (IP), progress the Company's research with the University of York and for general corporate purposes. Key expected future milestones are the manufacturing and scale up of key antibodies and reagents, that following performance testing in clinical trials are intended to become the core components of the Company's commercial test for the CIZ1B biomarker.
It is intended that the clinical trials and first commercial tests will be launched in the USA, in part because lung cancer is by far the leading cause of cancer death there and the US Preventive Services Task Force guidelines now recommends screening for 14.2 million at-risk adults*. With current take up of lung cancer screening tests at less than 10% of the at-risk population, the unmet need is for a simple blood test such as that being developed by Cizzle for the CIZ1B Biomarker.
The Company believes that as we enter this pivotal phase to accelerate the development, regulatory approval and launch of its biomarker diagnostic tests in North America the establishment of an independently financed and locally managed business is the appropriate route to take. BIO will be able to focus on bringing the Company's technology to market through building close relationships with key hospitals and clinical cancer centres and bringing together key opinion leaders and clinicians to drive adoption in this important market.
BIO will be led by Bill Behnke, who was appointed by the Company on 16 June 2022, to identify and facilitate growth within the USA through his network in the clinical and healthcare industry. He was responsible for putting in place Cizzle's co-operation with CorePath Laboratories. Through BIO, the Company will benefit from working closely with CorePath's College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) accredited specialist oncology reference laboratory in San Antonio, Texas, which brings together leading clinicians, scientists, academic affiliates and state of the art facilities.
Mr Behnke will be joined on the Board of BIO by Dr Ron Greeno, a veteran physician executive with 30 years of experience in the hospitalist practice management field. He was the founder of Cogent Healthcare and served as its EVP for strategy and Chief Medical Officer until its merger with Sound Physicians. He has also served in physician executive positions at IPC and TeamHealth. He was board certified in internal medicine, pulmonary medicine and critical care. He has been a senior advisor for government relations with the Center for Medicare and Medicaid Innovation ("CMMI"), also known as the 'Innovation Center', which was authorised under the Affordable Care Act and tasked with designing, implementing, and testing new health care payment models to address growing concerns about rising costs, quality of care, and inefficient spending. CMMI is managed by the Centers for Medicare and Medicaid Services (CMS).
BIO's ability to meet its financial obligations is dependant on a group of sophisticated high net worth investors in the USA. BIO intends to fully fund all expenditure on development, clinical trials, accreditation and marketing of diagnostic tests for the CIZ1B Biomarker, resulting in a free carry for the Company through to commercialization in North America. The Company will retain rights to improvements and inventions resulting from this commercialization process in the rest of the world.
The Company is now focused on finalising binding legal documentation with BIO and will make further announcements in due course, as appropriate.
Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
"We are delighted to have entered into this Memorandum of Understanding to create an independently financed and locally managed company that can build a business to serve the North American market. Apart from securing important guaranteed minimum and ongoing licensing revenue and free equity participation for the Company, there will be a significant reduction on planned costs associated with clinical trials and product accreditation. This represents a substantial opportunity to expand the Company's presence in North America through securing non-dilutive major investment and in building a high value dedicated US based leadership team to establish operations and drive adoption in this important market."
Bill Behnke, CEO of BIO, commented:
"Lung cancer is the leading cause of cancer deaths in the USA because of the unmet need for a simple blood test to aid physicians in the early detection of cancer. Through a strong appreciation of the potential value of the CIZ1B biomarker in improving patient survival rates we are very excited by the opportunity to secure an exclusive license from Cizzle for the North American market. Our investor group sees this as an important opportunity to make a major difference to lung cancer survival rates and we have already made progress in developing further relationships with major cancer hospitals as we seek endorsement from clinicians and key opinion leaders."
*The 2021 USPSTF lung cancer screening guidelines: a new frontier - The Lancet Respiratory Medicine
문의 :
Cizzle 생명공학 홀딩스 plc | IFC 자문을 통해 |
앨런 심스(집행 회장) |
알렌비 캐피탈 리미티드 | + 44 (0) 20 3328 5656 |
존 데파스퀄 | |
조지 페인 |
노붐증권 | + 44 (0) 20 7399 9400 |
콜린 로우버리 존 벨리스 |
IFC 자문 제한 | + 44 (0) 20 3934 6630 |
팀 멧칼프 | |
플로렌스 챈들러 |
Cizzle Biotechnology 소개
Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com
트위터 계정 @CizzlePlc 및 LinkedIn을 통해 회사를 팔로우할 수도 있습니다.
About Cizzle Bio Inc
Cizzle Bio Inc, a company registered in Texas USA, has been created by a group of high-net-worth individuals with a passion to improve cancer patient survival. Recognising that one of the main causes of poor survival rates for certain cancers and in particular, lung cancer, is because diagnosis is often when the disease is at an advanced state, there is an unmet need for a simple blood test that can be used to detect cancer early. BIO is led by Bill Behnke, who has been pioneering Cizzle Biotechnology's marketing activities in the USA and is an accomplished entrepreneur and performance-driven senior executive with an extensive background of success in funding and building healthcare businesses through direct sales, marketing, sales management, and business development. He is heavily engaged in charitable work for cancer, and served a nine-year tenure on the national board of the Leukemia and Lymphoma Society. He currently serves on the boards of the ASCO Foundation's Conquer Cancer; the AYA Cancer Foundation; The Wheeler Group; Children's Shelter of San Antonio; South Texas Blood and Tissue Center; and the Leukemia and Lymphoma Society.
About CorePath laboratories
Founded and headquartered in San Antonio, Texas as one of the few international laboratories with the ability to offer immunohistochemistry, cancer cytogenetics, molecular genetics and multicolour flow cytometry services at one location. CorePath brings academic expertise, compassion and state of the art technology to help physicians help their patients and achieve the most accurate time-sensitive results for early treatment.
함께 그들은 "생명을 돌보는 일"이라는 공통된 열정을 가진 고도로 전문화된 팀입니다.
CorePath는 미국 전역과 국제적으로 의료 서비스 제공자에게 광범위한 혈액 병리학 서비스를 제공합니다. 그들은 다음을 통해 바이오 제약 산업과 긴밀하게 협력합니다. 암 약물 연구 요구에 대한 관련 과학 및 치료 전문 지식을 갖춘 노련한 프로젝트 관리 팀. 보드 인증을 받은 병리학자 팀은 최첨단 기술을 사용하여 암을 정확하게 진단하기 위해 다양한 종양학 분야에서 세분화됩니다. 고객은 ICON, Alexion, Covance, Ventana(Roche) 및 Becton Dickenson을 포함합니다.
For more information, please see https://www.corepath.us/
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.